Open AccessTherapy of Age-related Exudative Macular Degeneration with Anti-vascular Endothelial Growth Factor Drugs: An Italian Real Life Study
Author(s) -
Silvia Rossi,
Carlo Gesualdo,
Antonio Tartaglione,
Giovan Battista Scazzi,
Anna Cristina D’Alessio,
Adele Ragucci,
Paolo Melillo,
Francesca Simonelli
Publication year - 2021
Publication title -
the open ophtalmology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 19
ISSN - 1874-3641
DOI - 10.2174/1874364102115010130
Subject(s) - medicine , aflibercept , macular degeneration , ranibizumab , ophthalmology , visual acuity , bevacizumab , surgery , chemotherapy
Aim: To evaluate the real utilization of ranibizumab and aflibercept in the daily management of patients with neovascular age-related macular degeneration (nAMD) treated at the Eye Clinic of Campania University L.Vanvitelli. Background: Therapy with anti-vascular endothelial growth factor represents the gold standard in wet age-related macular degeneration. There are nonreal life italian studies of this therapy in the literature. Objective: To analyze in our sample the post-therapy variations of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) observed at the end of a 12-month follow-up period. Methods: This real-life study analyzes 109 patients that underwent monthly checks for the first 4 months and then every 2 months until the end of the 12-month follow-up. The sample was first analyzed in its entirety, subsequently subdivided into 3 groups based on baseline BCVA, age, and the number of intravitreal injections performed, in order to identify possible predictive elements of the anti-VEGF response. Results: On average, patients underwent 4.16 ± 1.58 intravitreal anti-VEGF injections in 1 year. At the end of the 12-month follow-up, the patients’ average BCVA increased from 33.01 letters to 33.75 letters (+0.74 ± 9,4 letters), while the average CRT decreased from 346.86 µm to 265.39 µm (-81.47 ± 121 µm). Conclusion: The study shows the efficacy of anti-VEGF therapy in the stabilization of BCVA in nAMD, confirming the differences in visual outcomes compared to clinical trials, mainly for economic-organizational reasons.